Get the Stockscreener App
133.82
0.13%
0.17
After Hours:
133.49
-0.33
-0.25%
Apogee Therapeutics Inc stock is traded at $133.82, with a volume of 1.21M.
It is up +0.13% in the last 24 hours and up +51.50% over the past month.
Apogee Therapeutics Inc is a clinical-stage biotechnology company engaged in advancing optimized, novel biologics with the potential for differentiated efficacy and dosing in the inflammatory and immunology (I&I) markets, including for the treatment of atopic dermatitis (AD), asthma, eosinophilic esophagitis (EoE), chronic obstructive pulmonary disease (COPD), and other I&I indications. . Its antibody programs are designed to overcome the limitations of existing therapies by targeting well-established mechanisms of action and incorporating antibody engineering to optimize half-life and other properties.
See More
Previous Close:
$133.65
Open:
$133.55
24h Volume:
1.21M
Relative Volume:
0.51
Market Cap:
$10.06B
Revenue:
-
Net Income/Loss:
$-274.62M
P/E Ratio:
-30.92
EPS:
-4.3278
Net Cash Flow:
$-235.37M
1W Performance:
+0.24%
1M Performance:
+51.50%
6M Performance:
+69.39%
1Y Performance:
+250.87%
1-Day Range:
$133.54
$133.88
1-Week Range:
$133.18
$133.88
52-Week Range:
$34.34
$133.88
Apogee Therapeutics Inc Stock (APGE) Company Profile
Name
Apogee Therapeutics Inc
Sector
Industry
Phone
650-394-5230
Address
221 CRESCENT ST., WALTHAM
Compare APGE vs VRTX, REGN, ARGX, RVMD, ALNY
| Stocks | Price | Market Cap | Revenue | Net Income | Cash Flow | EPS |
|---|---|---|---|---|---|---|
APGE
Apogee Therapeutics Inc
|
133.82 | 10.05B | 0 | -274.62M | -235.37M | -4.3278 |
VRTX
Vertex Pharmaceuticals Inc
|
480.25 | 123.19B | 12.34B | 4.34B | 3.71B | 16.87 |
REGN
Regeneron Pharmaceuticals Inc
|
663.09 | 69.67B | 14.92B | 4.42B | 3.79B | 41.04 |
ARGX
Argen X Se Adr
|
876.25 | 54.58B | 4.16B | 1.29B | 734.26M | 19.58 |
RVMD
Revolution Medicines Inc
|
183.95 | 39.73B | 742.00K | -1.37B | -1.07B | -7.0731 |
ALNY
Alnylam Pharmaceuticals Inc
|
288.06 | 39.89B | 4.29B | 577.22M | 641.34M | 4.2086 |
Apogee Therapeutics Inc Stock (APGE) Upgrades & Downgrades
| Date | Action | Analyst | Rating Change |
|---|---|---|---|
| Mar-18-26 | Initiated | Truist | Hold |
| Jan-22-26 | Downgrade | RBC Capital Mkts | Outperform → Sector Perform |
| Jan-07-26 | Initiated | Wolfe Research | Peer Perform |
| Dec-17-25 | Initiated | Stephens | Overweight |
| Dec-10-25 | Initiated | Deutsche Bank | Buy |
| Nov-03-25 | Initiated | Craig Hallum | Buy |
| Oct-21-25 | Initiated | Mizuho | Outperform |
| Sep-25-25 | Initiated | RBC Capital Mkts | Outperform |
| Jul-07-25 | Reiterated | BTIG Research | Buy |
| Mar-13-25 | Initiated | Citigroup | Buy |
| Nov-25-24 | Initiated | Canaccord Genuity | Buy |
| May-10-24 | Initiated | BofA Securities | Buy |
| Dec-20-23 | Initiated | BTIG Research | Buy |
| Aug-08-23 | Initiated | Guggenheim | Buy |
| Aug-08-23 | Initiated | Jefferies | Buy |
| Aug-08-23 | Initiated | Stifel | Buy |
| Aug-08-23 | Initiated | TD Cowen | Outperform |
| Aug-08-23 | Initiated | Wedbush | Outperform |
View All
Apogee Therapeutics Inc Stock (APGE) Latest News
AbbVie, Apogee Therapeutics filed HSR July 6, setting up Aug. 5 expiration - MLex
Apogee Therapeutics (NASDAQ: APGE) backs AbbVie’s $135.11‑per‑share all‑cash deal - Stock Titan
Apogee Therapeutics stock hits all-time high at 133.88 USD - Investing.com
What This Apogee Insider Move Might Mean After a 247% Stock Run - The Motley Fool
Understanding Momentum Shifts in (APGE) - Stock Traders Daily
Apogee Therapeutics CEO Michael Henderson sells $2.67m in stock By Investing.com - Investing.com India
CEO Michael Henderson Sells 20,000 Shares of Apogee Therapeutics Inc (APGE) - GuruFocus
Apogee Therapeutics CEO Michael Henderson sells $2.67m in stock - Investing.com
Form 4 Apogee Therapeutics Inc For: 10 July By Investing.com - Investing.com South Africa
Apogee Therapeutics (APGE) CEO logs stock sale and 75,046-share charitable gift - Stock Titan
Apogee Therapeutics (APGE) Jumps Into Focus, Is The Stock Fully Valued? - Yahoo Finance
Blackstone pledges $1.3 billion to help develop Apogee skin drug - MSN
AbbVie files $10.9bn Apogee deal in Germany - MLex
AbbVie to buy Apogee Therapeutics for $10.9 billion in cash - MSN
Wellington-affiliates report 564,326 APGE shares (APGE) ownership update - Stock Titan
T. Rowe Price boosts Apogee Therapeutics holding to 772,969 shares (NASDAQ: APGE) - Stock Titan
FMR LLC reports 2.49M Apogee Therapeutics shares (NASDAQ: APGE) - Stock Titan
Enterprise value to EBIT forward of Apogee Therapeutics, Inc. – NASDAQ:APGE - TradingView
Price to earnings forward of Apogee Therapeutics, Inc. – NASDAQ:APGE - TradingView
My Takeaway On Apogee Therapeutics' Massive Cash Raise Humberto Cruz (GVA0ZiS739) - Mshale
Price to earnings forward of Apogee Therapeutics, Inc. – BOATS:APGE - TradingView
Apogee Therapeutics: My Take On Their Promising Eczema Drug Data Kb5089549 (eYX66guJPl) - Mshale
Enterprise value to EBITDA forward of Apogee Therapeutics, Inc. – NASDAQ:APGE - TradingView
Price to book forward of Apogee Therapeutics, Inc. – NASDAQ:APGE - TradingView
Apogee Therapeutics: AbbVie Acquisition And Merger Arbitrage Analysis APGE $APGE #APGE #stockmarket Diana Shnaider (BwfgwfruEs) - Mshale
Apogee Therapeutics | SCHEDULE 13G/A: Others - Moomoo
Apogee Therapeutics (APGE) Proxy filing Summary - Quartr
Apogee Therapeutics CMO Carl Dambkowski sells $730,070 in stock By Investing.com - Investing.com Australia
Form 4 Apogee Therapeutics Inc For: 2 July By Investing.com - Investing.com Nigeria
Apogee Therapeutics CMO Carl Dambkowski sells $730,070 in stock - Investing.com
Apogee Therapeutics (APGE) CMO sells shares, exercises options under 10b5-1 plan - Stock Titan
Apogee Therapeutics | 4: Statement of changes in beneficial ownership of securities-Officer Dambkowski Carl - Moomoo
APGEApogee Therapeutics Inc Revenue Breakdown - Finviz
AbbVie to buy Apogee Therapeutics (APGE) for $135.11 per share — significant premium - Stock Titan
Apogee Therapeutics stock hits all-time high at 133.32 USD By Investing.com - Investing.com Australia
Apogee Therapeutics stock hits all-time high at 133.32 USD - Investing.com
AbbVie shares fell after six-session winning streak - MSN
Form 144 APOGEE THERAPEUTICS INC For: 1 July By Investing.com - Investing.com Canada
H.C. Wainwright Keeps Buy Rating on Oruka (ORKA) After Apogee Acquisition News - Insider Monkey
Carl Dambkowski (APGE) 10b5-1 sales total $3.5M on 06/22/2026 - Stock Titan
Apogee Therapeutics | 144: Notice of proposed sale of securities pursuant to Rule 144 - Moomoo
Avoiding Lag: Real-Time Signals in (APGE) Movement - Stock Traders Daily
APGE News | APOGEE THERAPEUTICS INC (NASDAQ:APGE) - ChartMill
AbbVie said to be nearing a $10.9B deal to buy Apogee Therapeutics - MSN
AbbVie (ABBV) to Acquire Apogee Therapeutics - Insider Monkey
Apogee Therapeutics Cut to Hold From Buy by Deutsche Bank - Moomoo
Apogee Therapeutics, Inc. Actuals & Estimates (NASDAQ:APGE) - TradingView
Deal Dispatch: Penske Buys Vox Media's Digital Brands, AbbVie Acquires Apogee Therapeutics For $10.9 Bill - Benzinga
Mizuho Securities Downgrades Apogee Therapeutics(APGE.US) to Hold Rating, Raises Target Price to $135 - Moomoo
APGE Forecast — Price Target — Prediction for 2027 - TradingView
Apogee Therapeutics CEO Henderson sells $10.6m in common stock By Investing.com - Investing.com Australia
Apogee Therapeutics Inc Stock (APGE) Financials Data
Revenue
Net Income
Cash Flow
EPS
Apogee Therapeutics Inc Stock (APGE) Insider Trading
| Insider Trading | Relationship | Date | Transaction | Cost | #Shares | Value ($) | #Shares Total |
|---|---|---|---|---|---|---|---|
| Dambkowski Carl | Chief Medical Officer |
Jul 01 '26 |
Option Exercise |
22.86 |
4,125 |
94,298 |
183,373 |
| Dambkowski Carl | Chief Medical Officer |
Jul 01 '26 |
Sale |
132.74 |
5,500 |
730,070 |
177,873 |
5.60%
0.04%
Open in Yahoo
|
Open in Google
|
Open in Finviz
|
Open in MarketWatch
|
Open in EDGAR
|
Open in Reuters
Cap:
|
Volume (24h):